J&J, GSK's ViiV tout switching study showing patients prefer their long-acting HIV med Cabenuva over Gilead rival

To make Cabenuva the standard treatment option for HIV, Johnson & Johnson and GSK-owned ViiV Healthcare must first dethrone Gilead Sciences’ once-daily stalwart Biktarvy. Now, the partners have a clutch of data suggesting their long-acting injectable is popular among patients.